Syndax is a commercial stage oncology innovator seeking to develop first-in-class therapies in areas of significant unmet need such as acute leukemia and chronic graft-versus-host disease. Self-described commitment to scientific excellence.

Syndax

Domain Not Resolving

Google Font API

Google

Google Cloud

jQuery CDN

Vimeo

Google Cloud Global Multi-Region

Mobile Optimized

New Relic

Drupal

Chief Business Officer

Anjali Ganguli

Briggs Morrison

President and Chief Operating Officer

Michael Metzger

Chief Medical Officer

Michael Meyers

Chief Scientific Officer

Peter Ordentlich

Chief Commercial Officer (CCO)

Steve Sabus

Vice President of Clinical Operations

Barbara Schaeffler

Vice President, Pharmaceutical Development & Manufacturing

Bret Shirley

Vice President, Head of Drug Safety and Pharmacovigilance

Dennis O'Brien

Vice President

Jerry McGeehan

Dennis Podlesak

Kim P. Kamdar

Artthur M. Pappas

Pierre Legault

Keith A Katkin

Jennifer Jarrett

William Meury

Chief Scientific Officer and Founder

Keith A. Goldan

Chief Financial Officer

Daphne Karydas

Matthew G. Nerney

Kate Madigan

Steven Closter

Chief Commercial Officer

President, Head of Research & Development

Luke Albrecht

General Counsel and Secretary

Health Care Companies that Exited (Top 10K)

Pharmaceutical Companies that Exited

Massachusetts Companies (Top 10K)

Hedge Fund Funded Companies

Syndax Pharmaceuticals is a clinical-stage pharmaceutical company that focuses on an HDAC inhibitor for solid tumors and hematological tumors. It offers therapies to treat solid tumors and lung, breast, and hematological cancer. The company is developing axatilimab, a monoclonal antibody that blocks the colony-stimulating factor 1 (CSF-1) receptor, in development for chronic Graft versus Host Disease, and entinostat, a class I HDAC inhibitor.

Syndax Pharmaceuticals pipeline includes and SNDX-5613, a highly selective inhibitor of the Menin–MLL binding interaction, in development for the treatment of patients with MLLr and NPM1 acute leukemias.

Post-IPO Equity - Syndax Pharmaceuticals

AI Life Sciences Investments LLC

Biotechnology Value Fund

Boxer Capital

Hercules Capital

Post-IPO Debt - Syndax Pharmaceuticals

Delos Capital

Fidelity

Series C - Syndax Pharmaceuticals

Debt Financing - Syndax Pharmaceuticals

Computer and Software Services and Scientific Services

Waltham

Massachusetts

United States

North America

Syndax Pharmaceuticals

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Citigroup Maintains Buy on Syndax Pharmaceuti...

Syndax Pharmaceuticals target cut by BofA on FDA delay

Stifel cuts Syndax Pharma target on FDA delay, retains Buy tag

Syndax Pharma Shares Fall Premarket After FDA Extends Revumenib Review

Syndax: Gearing Up For Launches (NASDAQ:SNDX)

Stifel raises Syndax Pharma stock target on drug approval optimism By Investing.com

Hong Kong

Asia

India

Malaysia

Italy

Europe

HTML5

Gravity Forms

jQuery

Microsoft Outlook

Cloudflare CDN

Modernizr

Office 365

Google Analytics

Google Tag Manager

Adobe Fonts

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.

Syndax Pharmaceuticals, Inc.

industry_trends_dossier

news_impact_assignment_basic

key_people

company_dossier

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

network

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

events

strategic_challenges

network_mapping

industry_trends

transactions_dossier

strategic_challenges_dossier

network_onboarding

company_summary

regulatory_analysis

industry_analysis

swot_dossier

competition_analysis

financial_legal_advisories

merger_acquisitions

logo

swot_analysis

financial_analysis

news_advanced

purchaser_profile

news_impact_assignment_advanced

signals

news_processing_advanced

financial_statements

private_financials

funding_rounds_analysis

company_structure

crunchbase_trigger

crunchbase_profile

peers

news_basic

valuation

customer_profile

industry trends dossier	dataroom
company dossier	dataroom
network	dataroom
network mapping	dataroom
transactions dossier	dataroom
network onboarding	dataroom
news impact assignment basic	general
public peers	general	Sep 13, 2024 8:56 AM	e6491794
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
news advanced	general
news impact assignment advanced	general
signals	general	Sep 13, 2024 8:56 AM	4c83e768
news processing advanced	general
crunchbase trigger	general	Oct 31, 2024 9:55 AM	59594af1
crunchbase profile	general	Oct 31, 2024 11:37 AM	b5b5e9be
peers	general	Sep 13, 2024 8:56 AM	fcfc54c9
news basic	general	Sep 13, 2024 8:56 AM	e1ad3370
events	markdown
bundesanzeiger	filings
regulatory analysis	company_analysis
industry analysis	company_analysis
competition analysis	company_analysis
financial legal advisories	company_analysis
merger acquisitions	company_analysis
swot analysis	company_analysis
financial analysis	company_analysis
funding rounds analysis	company_analysis
company structure	company_analysis
logo	meta	Sep 13, 2024 8:56 AM	1a6fbe69
purchaser profile	merger_acquisitions
private financials	financials
customer profile	customers

COM:SYNDAX

Syndax

Last Close

18.92

31/10 16:09

Market Cap

1.93B

Beta: -

Volume Today

230.49K

Avg: -